Senolytic Treatment with Dasatinib and Quercetin Confirmed to Reduce the Burden of Senescent Cells in Human Patients

Setting aside the mice genetically engineered to destroy senescent cells, the combination of dasatinib and quercetin is the oldest of the senolytic treatments used in animal studies. Senolytic therapies are those that selectively destroy senescent cells in old tissues in order to produce rejuvenation, turning back the progression of numerous age-related conditions. Unusually for early stage research, these initial senolytics are actually quite effective, considered in the grand scheme of things. Thus they have moved directly to human trials in some cases. The first data on their ability to produce the same outcomes in humans as in mice emerged this year, and more data will continue to roll out over the next few years as the first trials run and complete. The results reported in today's open access paper provide an important demonstration for those not yet convinced that the animal data is relevant. Meanwhile, the older members of the self-experimentation community have been using dasatinib, quercetin, and a few other senolytics for a few years now on the strength of the animal data and the whisper network of positive outcomes. Further, groups such as the Age Reversal Network are attempting to build physician networks and support for off-label use of senolytics. While senescent cells are important in a range of beneficial processes, from cancer suppression, to the Hayflick limit, to wound healing, their presence is temporary in all such cases. Near all are destro...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs

Related Links:

Publication date: Available online 19 October 2019Source: Practical Radiation OncologyAuthor(s): Barry S. Rosenstein
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
ConclusionThese findings suggest that targeted research and interventions are necessary to address the specific needs of rural lymphoma patients and survivors. To address the disparity in health outcomes within rural populations, health care professionals and investigators can utilize these data to engage rural patients in treatment decision-making and research planning.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionThe better prognosis in young patients is presumably due to their better physiological reserve and lower incidence of comorbidities. Efforts should be made in younger patients to diagnose early and treat aggressively.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
We examined racial differences in hospitalization outcomes; length of stay (LOS) in hospital, mortality in hospital, post-operative complications in patients who underwent hysterectomy and discharge disposition. Patients were matched on age at primary diagnosis, insurance status, residential region, and median income of residential area, modified Deyo comorbidity index, stage of disease and treatment. Categorical outcomes were analyzed by conditional logistic regression accounting for matched study design and odds ratios (95%CI) were reported. LOS was analyzed using t-test and beta estimate for difference in means was repo...
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 October 2019Source: Acta Pharmaceutica Sinica BAuthor(s): Hui Deng, Weimin LiAbstractMonoacylglycerol lipase (MAGL) is a serine hydrolase that plays a crucial role catalysing the hydrolysis of monoglycerides into glycerol and fatty acids. It links the endocannabinoid and eicosanoid systems together by degradation of the abundant endocannabinoid 2-arachidaoylglycerol into arachidonic acid, the precursor of prostaglandins and other inflammatory mediators. MAGL inhibitors have been considered as important agents in many therapeutic fields, including anti-nociceptive, anxiolytic, anti-infl...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 October 2019Source: Acta Pharmaceutica Sinica BAuthor(s): Honggang Xiang, Jifa Zhang, Congcong Lin, Lan Zhang, Bo Liu, Liang OuyangAbstractAutophagy, defined as a scavenging process of protein aggregates and damaged organelles mediated by lysosomes, plays a significant role in the quality control of macromolecules and organelles. Since protein kinases are integral to the autophagy process, it is critically important to understand the role of kinases in autophagic regulation. At present, intervention of autophagic processes by small-molecule modulators targeting specific kinases has bec...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
This study aimed to investigate the anti-OSCC potential of novel endostatin-derived polypeptide PEP06 as a cluster-dissociating therapeutic agent in vitro. Firstly, we found marked enrichment of αv integrin in collectively invading multicellular clusters in human OSCCs. Our study revealed that metastatic progression of OSCC was associated with augmented immunostaining of αv integrin in cancerous lesions. Following PEP06 treatment, cell clustering on fibronectin, migration, multicellular aggregation, anchorage-independent survival and colony formation of OSCC were significantly inhibited. Moreover, PEP06 suppres...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 October 2019Source: Acta Pharmaceutica Sinica BAuthor(s): Zongru Jiang, Li Wang, Xuesong Liu, Cheng Chen, Beilei Wang, Wenliang Wang, Chen Hu, Kailin Yu, Ziping Qi, Qingwang Liu, Aoli Wang, Jing Liu, Guangchen Hong, Wenchao Wang, Qingsong LiuAbstractAngiogenesis is an essential process in tumor growth, invasion and metastasis. VEGF receptor 2 (VEGFR2) inhibitors targeting tumor angiogenic pathway have been widely used in the clinical cancer treatment. However, most of currently used VEGFR2 kinase inhibitors are multi-target inhibitors which might result in target-associated side effect...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurposeThe identification of biomarkers characterizing the invasive potential of bladder cancer could enhance the clinical management of individual patients and therefore improve prognosis. The aim of this study was to define a miRNA panel in tumor tissues as well as in urinary extracellular vesicles (EVs) for discriminating muscle-invasive bladder cancer (MIBC) from non-muscle-invasive bladder cancer (NMIBC).MethodsmiRNA expression was analyzed in 24 formalin-fixed, paraffin-embedded (FFPE) tumor samples by microarray analysis and was further validated by qRT-PCR in 56 FFPE tumor samples as well as in 37 urinary E...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Apples | Biotechnology | Cancer | Cancer & Oncology | Cardiology | Chronic Kidney Disease | Clinical Trials | Diabetes | Diets | Eating Disorders & Weight Management | Endocrinology | Environmental Health | Genetics | Heart | Heart Disease | High Fat | Insulin | Liver | Nutrition | Obesity | Oral Cancer | Orthopaedics | Osteoporosis | Proteinuria | Research | Scleroderma | Skin | Statistics | Study | Urology & Nephrology